LiRIS® Research Study in IC Patients with Hunner's Ulcers & Lesions

LiRIS® Research Study in IC Patients with Hunner’s Ulcers & Lesions

This is the first of two clinical trial announcements released by the ICN today, both featuring clinical trials for interstitial cystitis. This first study is evaluating the use of LiRIS in the treatment of Hunner’s lesions, aka ulcers. Early LiRIS pain studies found that some Hunner’s ulcers were responding to treatment, a result we have not seen with any other treatment. If successful, this new study could pave the way for a new, much needed therapy for the most severe form of IC. If you have struggled with bladder lesions or ulcers and are able to visit this research site (Royal OK, MI), I think this study is worth learning more about. – Jill Osborne MA – ICN President

TARIS Biomedical® has initiated an open label Phase 1b research study investigating LiRIS in women with Interstitial Cystitis (IC) with a history of Hunner’s lesions in the bladder. The study is currently being conducted in Michigan, and may include up to 3 centers in the United States.

LiRIS is an investigational product (not approved by FDA) that combines the local anesthetic lidocaine with a small, flexible delivery device. LiRIS is designed to continuously provide lidocaine to the bladder over an extended period. LiRIS is inserted into the bladder via a cystoscope and remains in the bladder for 14 days. At the end of the 14-day period, LiRIS is removed via a second cystoscopic procedure. Study participants will need to go to the clinic for study visits and assessments, and will be asked to complete questionnaires, including a voiding frequency diary, both at home during the study and throughout a follow-up period thereafter.

You may be eligible if you:

Have been diagnosed with IC with a history of Hunner’s lesions in the bladder
Experience pain and voiding symptoms associated with your IC
Are able and willing to complete the questionnaires and voiding frequency diary
Can comply with the full visit schedule and all associated procedures

For More Details:

Please go to clinicaltrials.gov for more information and site locations near you. Use trial identifier NCT01879683.

Contact: Maureen Cooney, RN, William Beaumont Hospital – Department of Urology Research at 248-551-3355

By Jill Osborne|2017-01-31T13:40:37-08:00October 17th, 2013|Clinical Trials, Industry News, Latest Research, News, Our Blog, Research, Treatments|Comments Off

About the Author: Jill Osborne

My Google Profile+ Jill Heidi Osborne is the president and founder of the Interstitial Cystitis Network, a health education company dedicated to interstitial cystitis, bladder pain syndrome and other pelvic pain disorders. As the editor and lead author of the ICN and the IC Optimist magazine, Jill is proud of the academic recognition that her website has achieved. The University of London rated the ICN as the top IC website for accuracy, credibility, readability and quality. (Int Urogynecol J - April 2013). Harvard Medical School rated both Medscape and the ICN as the top two websites dedicated to IC. (Urology - Sept 11). For many years, Jill served on the Congressionally Directed Medical Research Panel (US Army) where she collaborated with researchers to evaluate new IC research studies for possible funding. Jill has conducted and/or collaborates on a variety of IC research studies on new therapeutics, pain care, sexuality, the use of medical marijuana, menopause and the cost of treatments, shining a light on issues that influence patient quality of life. An IC support group leader and national spokesperson for the past 20 years, she has represented the IC community on radio, TV shows, at medical conferences. She has written hundreds of articles on IC and its related conditions. Jill has a Bachelors Degree in Pharmacology and a Masters in Psychology, Jill was named Presidential Management Intern (aka Fellowship) while in graduate school. (She was unable to earn her PhD due to the onset of her IC.) She spends the majority of her time providing WELLNESS COACHING for patients in need and developing new, internet based educational and support tools for IC patients, including new live IC Support Group Meetings via Youtube and the “Living with IC” video series. Jill was diagnosed with IC at the age of 32 but first showed symptoms at the age of 12.